Record Date
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova has approved its audited financial results for Q4 and FY ended March 31, 2026. The company reported consolidated revenue from operations of Rs. 82,250 million for FY2026, up 14.4% from Rs. 71,921 million in FY2025. However, profit after tax declined significantly to Rs. 5,393 million from Rs. 9,433 million in the previous year. The Board recommended a final dividend of Rs. 5 per equity share (500% on face value of Re. 1), totaling approximately Rs. 796 million, subject to shareholder approval. July 24, 2026 has been fixed as the record date for determining shareholders eligible for the dividend. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on the financial statements. Exceptional items included a gain of Rs. 236 million from sale of assets and expenses of Rs. 535 million related to temporary suspension of manufacturing operations at a Canadian facility for remediation purposes.
The stock may face pressure due to significant PAT decline of approximately 43% despite revenue growth. However, the dividend recommendation and clean audit opinion with unmodified reports provide some positive support for investor sentiment.